Some studies suggest that CTNNB1 mutations correlate with less aggressive tumor behavior, reduced invasiveness, lower serum alpha-fetoprotein (AFP) levels, and better-differentiated HCC [89,90,91]. This evidence concerns the gene CTNNB1 and neoplasm.